Editorial: Bacteriophages and Their Lytic Enzymes as Alternative Antibacterial Therapies in the Age of Antibiotic Resistance

Carlos São-José¹, Ana Rita Costa², Luís D R Melo^{3

4}

Affiliations

¹ Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
² Department of Bionanosciences, Kavli Institute of Nanoscience, Delft University of Technology, Delft, Netherlands.
³ CEB - Centre of Biological Enginering, LIBRO-Laboratório de Investigação em Biofilmes Rosário Oliveira, University of Minho, Braga, Portugal.
⁴ LABBELS - Associate Laboratory, Braga/Guimarães, Portugal.

PMID: 35401457
PMCID: PMC8991073
DOI: 10.3389/fmicb.2022.884176

Editorial

Editorial: Bacteriophages and Their Lytic Enzymes as Alternative Antibacterial Therapies in the Age of Antibiotic Resistance

Carlos São-José et al. Front Microbiol. 2022.

. 2022 Mar 25:13:884176.

doi: 10.3389/fmicb.2022.884176. eCollection 2022.

Authors

Carlos São-José¹, Ana Rita Costa², Luís D R Melo^{3

4}

Affiliations

¹ Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
² Department of Bionanosciences, Kavli Institute of Nanoscience, Delft University of Technology, Delft, Netherlands.
³ CEB - Centre of Biological Enginering, LIBRO-Laboratório de Investigação em Biofilmes Rosário Oliveira, University of Minho, Braga, Portugal.
⁴ LABBELS - Associate Laboratory, Braga/Guimarães, Portugal.

PMID: 35401457
PMCID: PMC8991073
DOI: 10.3389/fmicb.2022.884176

No abstract available

Keywords: antibiotic resistance; bacteriophage (phage); enzybiotics; lysins; phage therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

Editorial on the Research Topic Bacteriophages and Their Lytic Enzymes as Alternative Antibacterial Therapies in the Age of Antibiotic Resistance

Cited by

Resistance, Tolerance, Virulence and Bacterial Pathogen Fitness-Current State and Envisioned Solutions for the Near Future.
Lazar V, Oprea E, Ditu LM. Lazar V, et al. Pathogens. 2023 May 22;12(5):746. doi: 10.3390/pathogens12050746. Pathogens. 2023. PMID: 37242416 Free PMC article. Review.
The potential use of bacteriophages as antibacterial agents in dental infection.
Hosseini Hooshiar M, Salari S, Nasiri K, Salim US, Saeed LM, Yasamineh S, Safaralizadeh R. Hosseini Hooshiar M, et al. Virol J. 2024 Oct 18;21(1):258. doi: 10.1186/s12985-024-02510-y. Virol J. 2024. PMID: 39425223 Free PMC article. Review.
Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens.
Zhydzetski A, Głowacka-Grzyb Z, Bukowski M, Żądło T, Bonar E, Władyka B. Zhydzetski A, et al. Molecules. 2024 Aug 27;29(17):4065. doi: 10.3390/molecules29174065. Molecules. 2024. PMID: 39274911 Free PMC article. Review.
The applications of animal models in phage therapy: An update.
Mehmood Khan F, Manohar P, Singh Gondil V, Mehra N, Kayode Oyejobi G, Odiwuor N, Ahmad T, Huang G. Mehmood Khan F, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2175519. doi: 10.1080/21645515.2023.2175519. Epub 2023 Mar 19. Hum Vaccin Immunother. 2023. PMID: 36935353 Free PMC article. Review.
BL02, a phage against carbapenem- and polymyxin-B resistant Klebsiella pneumoniae, isolated from sewage: A preclinical study.
Liang Z, Shi YL, Peng Y, Xu C, Zhang C, Chen Y, Luo XQ, Li QM, Zhao CL, Lei J, Yuan ZQ, Peng YZ, Song BQ, Gong YL. Liang Z, et al. Virus Res. 2023 Jul 2;331:199126. doi: 10.1016/j.virusres.2023.199126. Epub 2023 Apr 29. Virus Res. 2023. PMID: 37105436 Free PMC article.

See all "Cited by" articles

References

1. Chan B. K., Abedon S. T., Loc-Carrillo C. (2013). Phage cocktails and the future of phage therapy. Fut. Microbiol. 8, 769–783. 10.2217/fmb.13.47 - DOI - PubMed
1. Danis-Wlodarczyk K. M., Wozniak D. J., Abedon S. T. (2021). Treating bacterial infections with bacteriophage-based enzybiotics: in vitro, in vivo and clinical application. Antibiotics 10:1497. 10.3390/antibiotics10121497 - DOI - PMC - PubMed
1. Deng S., Xu Q., Fu Y., Liang L., Wu Y., Peng F., et al. . (2021). Genomic analysis of a novel phage infecting the Turkey pathogen Escherichia coli APEC O78 and its endolysin activity. Viruses 13:1034. 10.3390/v13061034 - DOI - PMC - PubMed
1. Feldman C., Anderson R. (2021). The role of co-infections and secondary infections in patients with COVID-19. Pneumonia 13:5. 10.1186/s41479-021-00083-w - DOI - PMC - PubMed
1. Gutierrez D., Briers Y. (2021). Lysins breaking down the walls of Gram-negative bacteria, no longer a no-go. Curr. Opin. Biotechnol. 68, 15–22. 10.1016/j.copbio.2020.08.014 - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Editorial: Bacteriophages and Their Lytic Enzymes as Alternative Antibacterial Therapies in the Age of Antibiotic Resistance

Affiliations

Editorial: Bacteriophages and Their Lytic Enzymes as Alternative Antibacterial Therapies in the Age of Antibiotic Resistance

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources